<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179423</url>
  </required_header>
  <id_info>
    <org_study_id>GNC-301</org_study_id>
    <nct_id>NCT03179423</nct_id>
  </id_info>
  <brief_title>Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years</brief_title>
  <acronym>RAINBOW-T1D</acronym>
  <official_title>Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeNeuro Australia PTY Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern Star Research Pty Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeNeuro Australia PTY Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous
      Multiple Sclerosis associated RetroVirus (MSRV), which could play a critical role in
      different autoimmune disorders, notably type 1 diabetes (T1D).

      This study is a multicentre study evaluating for the first time the safety and efficacy of
      GNbAC1 in T1D subjects for a first bouble-blind period of 20 weeks followed by an optional
      open-label period of 24 weeks. The primary objective of the study is to assess the safety and
      tolerability of six consecutive 4-weekly doses of GNbAC1 in subjects with T1D. Secondary
      objectives are to determine the pharmacodynamic response to GNbAC1 on biomarkers of T1D.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The first part of the trial is double-blind and the second part is open-label with all participants receiving the active treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of GNbAC1 in patients with recent onset type 1 diabetes: Serious Adverse Events (SAE) and Adverse Events (AE)</measure>
    <time_frame>Week 1 to 24/48</time_frame>
    <description>Serious Adverse Events (SAE) and Adverse Events (AE)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>GNbAC1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly IV repeated dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Monthly IV repeated dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNbAC1</intervention_name>
    <description>Monthly IV repeated dose</description>
    <arm_group_label>GNbAC1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Monthly IV repeated dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Subjects diagnosed with type 1 diabetes in the 4 years prior to signed informed
             consent;

          -  Peak stimulated C-peptide of ≥0.2 nmol/L during a mixed meal tolerance test performed
             during the Screening period;

          -  18 to 55 years of age (both inclusive);

          -  Body weight &gt;40 to ≤100 kg;

          -  Subjects positive for at least one diabetes-associated autoantibody (insulin,
             glutaminic-acid-decarboxylase-65 [GAD-65], tyrosine phosphatase-related antigen 2
             [IA-2], ZnT8 or islet-cell antibody [ICA]).

        Main Exclusion Criteria:

          -  Subjects with type 2 diabetes;

          -  Pregnant and nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Macquarie University Hospital</name>
      <address>
        <city>Macquarie University</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIM Centre</name>
      <address>
        <city>Merewether</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Sydney Local Health District - Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Research Centre</name>
      <address>
        <city>Ipswich</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Ltd and Mater Medical Research Institute Limited</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Hospital and Health Service</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Adelaide Local Health Network - Repatriation General Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Adelaide Local Health Network Incorporated, operating as Lyell McEwin Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Health</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital (Melbourne) Limited</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barwon Health - University of Geelong</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg Repatriation Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keogh Institute of Medical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>T1D</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Multiple Sclerosis associated retrovirus MSRV</keyword>
  <keyword>Human Endogenous Retrovirus Type W (HERV-W)</keyword>
  <keyword>GNbAC1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

